Candel Therapeutics (NASDAQ:CADL) specializes in the development of oncolytic viral therapies, a pioneering approach aimed at harnessing the power of viruses to selectively attack and destroy cancer cells while stimulating a potent, systemic immune response against the cancer. The company's innovative pipeline is focused on addressing a wide range of solid tumor types through robust clinical programs. With ongoing projects aimed at enhancing the efficacy and safety of cancer treatments, Candel Therapeutics is committed to improving patient outcomes and advancing the field of immuno-oncology. Their objective is to revolutionize cancer therapy by developing treatments that offer a better quality of life and survival rates for patients battling cancer.